A Prediction Model for Chemotherapy-Induced Thrombocytopenia Based on Real-World Data and a Close Relationship Between AST/ALT Ratio and Platelet Count in Patients with Solid Tumors
Bingxin Song,Shishi Zhou,Chenghui Li,Hongjuan Zheng,Xia Zhang,Xiayun Jin,Jianfei Fu,Huixian Hu
DOI: https://doi.org/10.2147/IJGM.S383349
IF: 2.145
2022-11-02
International Journal of General Medicine
Abstract:Bingxin Song, 1 Shishi Zhou, 2 Chenghui Li, 2 Hongjuan Zheng, 2 Xia Zhang, 2 Xiayun Jin, 2 Jianfei Fu, 2 Huixian Hu 1 1 Department of Medical Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, People's Republic of China; 2 Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, People's Republic of China Correspondence: Jianfei Fu, Department of Medical Oncology, Zhejiang University Jinhua Hospital, 351 Mingyue Road, Jinhua, 321000, Zhejiang Province, People's Republic of China, Fax +86-579-82552856, Email Huixian Hu, Department of Medical Hematology, Zhejiang University Jinhua Hospital, 351 Mingyue Road, Jinhua, Zhejiang Province, 321000, People's Republic of China, Fax +86-579-82136611, Email Objective: Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy dose delay or reduction, and even serious bleeding. This study aimed to develop a CIT-predicting model based on the laboratory indices of cancer patients undergoing chemotherapy. Material and Methods: From Jun 1, 2017 to Dec 30, 2021, a total of 2043 patients who had received 7676 cycles of chemotherapy were retrospectively enrolled. A logistic regression analysis was performed to identify predictive factors, on the basis of which a nomogram model for predicting CIT was established. A bootstrapping technique was applied for internal validation. A generalized additive mixed model (GAMM) was constructed to analyze the trends in the changes of aspartate aminotransferase (AST), ratio of AST to alanine transaminase (ALT) (AST/ALT ratio), and platelet (PLT) count in patients with solid tumors. P values ≤ 0.05 were considered statistically significant. Results: The patient-based incidence of CIT was 20.51% and the cycle-based incidence was 10.01%. The multivariate analysis showed that AST level, AST/ALT ratio, and total bilirubin (Tbil), white blood cell (WBC), platelet (PLT), hemoglobin (Hb) levels were significantly associated with the risk of CIT. The GAMM analysis showed that PLT level was inversely associated with AST/ALT ratio and AST level, more significantly with AST/ALT ratio. And both exhibited statistically predictive abilities for CIT. The model achieved an area under the receiver operating characteristic curve (AUC) of 0.793, a sensitivity of 0.543 and a specificity of 0.930. Conclusion: The AST/ALT ratio was inversely associated with the CIT risk in cancer patients. The GAMM model based on laboratory indices presented a high accuracy in predicting the risk of CIT, and a potential to be translated into clinical management. Keywords: chemotherapy-induced thrombocytopenia, solid tumors, AST/ALT-ratio, prediction model Chemotherapy-induced thrombocytopenia (CIT), a most common complication in cancer patients receiving myelosuppressive chemotherapy, emerges as the peripheral platelet count falls below 100×10 9 /L, with or without bleeding. 1 In the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE 4.03) established by the National Institute of Health (NIH), thrombocytopenia refers to a decrease in the number of platelets (PLT) in the blood specimen, involving four grades: grade 1, PLT count < low limit of normal (LLN) of 75,000/mm 3 or 75.0×10 9 /L; grade 2, PLT count <75,000–50,000/mm 3 or <75.0–50.0×10 9 /L; grade 3, PLT count <50,000–25,000/mm 3 or <50.0–25.0×10 9 /L; grade 4, PLT count <25,000/mm 3 or <25.0×10 9 /L. Prior studies estimated that more than 30% of patients with solid tumors experienced thrombocytopenia, 2 while the incidence of CIT in hematological tumors reached 75%. 3 CIT may lead to chemotherapy dose delay or reduction, and even serious bleeding, which increases the expenditure and worsens the prognosis. 4 Serum transaminases aspartate transaminase (AST) and alanine transaminase (ALT) are routinely measured to evaluate liver function. ALT is involved in the glucose-alanine cycle, interchange between alanine and pyruvate, and regeneration of glucose consumed by muscle. AST acts in aerobic glycolysis through relocating nicotinamide adenine dinucleotide (NADH) within the mitochondria. These transaminase reactions are essential to the metabolism in muscle and liver cells. 5 AST/ALT ratio, also termed as De Ritis ratio, has also been proven as an efficient index to diagnose many non-hepatic diseases. 6 Moreover, it is also an independent prognostic factor for several cancer entities. 7–11 Besides, a recent study has sugge -Abstract Truncated-
medicine, general & internal